Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study

BACKGROUND: TAS-102 (trifluridine and tipiracil hydrochloride; a novel combination oral nucleoside anti-tumor agent) has recently received regulatory approval for patients with refractory metastatic colorectal cancer (mCRC). Internal review of data at a single-institution showed a trend towards bett...

Descripción completa

Detalles Bibliográficos
Autores principales: Kasi, Pashtoon M., Kotani, Daisuke, Cecchini, Michael, Shitara, Kohei, Ohtsu, Atsushi, Ramanathan, Ramesh K., Hochster, Howard S., Grothey, Axel, Yoshino, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944251/
https://www.ncbi.nlm.nih.gov/pubmed/27412464
http://dx.doi.org/10.1186/s12885-016-2491-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944251/
https://www.ncbi.nlm.nih.gov/pubmed/27412464
http://dx.doi.org/10.1186/s12885-016-2491-y

Ejemplares similares